GlassScriptPhysician profile
Michael H Rizkalla
NPI 1477717791
$2,917.45
in general payments reported to CMS, 2019-2025
35 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $184 · 2021: $62.44 · 2022: $533 · 2023: $588 · 2024: $196 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.68 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $415.23 | 2019-2025 | Xtampza, Belbuca |
| Relievant Medsystems, INC. | $309.60 | 2022 | |
| Medtronic USA, INC. | $241.95 | 2019 | |
| Boston Scientific Corporation | $147.76 | 2019-2025 | General - Therapies, Infinion 16, General - Pain Management |
| Foundation Fusion Solutions, LLC | $145.57 | 2023-2025 | |
| Medtronic, INC. | $145.10 | 2022 | |
| Spr Therapeutics, INC | $144.00 | 2022-2023 | Sprint Pns System |
| Sonex Health, INC. | $105.49 | 2020 | |
| Si-Bone, INC. | $95.96 | 2023-2024 | |
| Mdd US Operations, LLC | $87.62 | 2019 | |
| Biodelivery Sciences International, INC. | $73.46 | 2019-2020 | |
| Pacira Therapeutics, INC. | $66.08 | 2019 | |
| Forte Bio-Pharma LLC | $50.25 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Valinor Pharma, LLC | $47.93 | 2023-2025 | Movantik |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $42.12 | 2019-2023 | Euflexxa |
| Kaleo, INC. | $29.44 | 2019 | |
| Ibsa Pharma INC. | $28.01 | 2023 | Tirosint, Licart |
| Merz North America, INC. | $27.95 | 2019 | |
| Daiichi Sankyo INC. | $27.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.64 | 2019 | |
| Merz Pharmaceuticals, LLC | $25.49 | 2023 | Xeomin |
| Nevro Corp. | $22.94 | 2021 | |
| Fidia Pharma USA INC. | $21.26 | 2023 | Triluron |
| Avanos Medical | $20.04 | 2024 | Trays- All |
| Curonix LLC | $19.55 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Bioventus LLC | $18.80 | 2019 | |
| Abbvie INC. | $16.86 | 2023 | Qulipta, Ubrelvy |
| Averitas Pharma INC. | $15.93 | 2024 | Qutenza |
| Scilex Pharmaceuticals INC. | $14.77 | 2019 | |
| Assertio Therapeutics, INC. | $14.61 | 2019 | |
| Shionogi INC | $11.47 | 2019 | |
| Saluda Medical Americas, INC. | $11.39 | 2023 | Evoke Scs |
| Uswm, LLC | $11.38 | 2021 | |
| Zyla Life Sciences, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rizkalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.